Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis.  Pediatric Pulmonology.  53:E21-E23. 2018
2016 Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.  Current Medical Research and Opinion.  32:1789-1795. 2016
2015 Quantitative sinonasal symptom assessment in an unselected pediatric population with cystic fibrosis 2015
2010 IL-10 delivery by AAV5 vector attenuates inflammation in mice with pseudomonas pneumonia 2010
2009 Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis.  American Journal of Respiratory Cell and Molecular Biology.  41:367-375. 2009
2009 Cost-effective airway cultures in the cystic fibrosis patient 2009
2008 Oral instillation with surfactant phospholipid: A reliable alternative to intratracheal injection in mouse studies.  Laboratory Animals.  42:294-304. 2008
2005 Enhancing rAAV vector expression in the lung.  Journal of Gene Medicine.  7:842-850. 2005
2005 Emergency preparedness for the chronically ill.  American Journal of Nursing.  105:68-72. 2005
2004 Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line.  Molecular Therapy.  10:562-573. 2004
2002 Adeno-associated viral vectors for CF gene therapy..  Methods in Molecular Medicine.  70:599-608. 2002
2000 Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients 2000
1997 Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.  Clinical immunology and immunopathology.  85:73-82. 1997
1993 Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers.  International Journal of Clinical and Laboratory Research.  23:95-101. 1993
1991 Immunosuppressive effects of fish oil in normal human volunteers: Correlation with the in vitro effects of eicosapentanoic acid on human lymphocytes.  Clinical immunology and immunopathology.  61:161-176. 1991

Research Overview

  • Cystic Fibrosis, Asthma, Patient Safety, Lung inflammation

    • Principal Investigator On

    Investigator On

  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2020 - 2023
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2020 - 2022
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2018 - 2022
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2017 - 2022
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2021 - 2022
  • Private Grant  awarded by ELECTROMED, INC. 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Airways Clinical Research Centers (ALA-ACRC) Network  awarded by American Lung Association 2020 - 2021
  • Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma  awarded by American Lung Association 2019 - 2021
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^ 2020 - 2021
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • Role of Body Fat Distribution in Metabolic and Pulmonary Decline in CF  awarded by Emory University 2019 - 2021
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation ^ 2017 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Airways Clinical Research Centers (ACRC) Network  awarded by American Lung Association 2019 - 2020
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^ 2019 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2018 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019 - 2020
  • ANDDi - American Lung Association Novel Digital Diary Trial  awarded by American Lung Association 2018 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2017 - 2019
  • Airways Clinical Research Centers (ACRC) Network  awarded by American Lung Association 2018 - 2019
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^ 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • Implementation of the Depression and Anxiety Guideline: Award for a Mental Health Coordinator  awarded by Cystic Fibrosis Foundation ^ 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Airways Clinical Research Centers (ACRC)  awarded by American Lung Association 2017 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^ 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Development of Standardized Measures of Barriers to Treatment Adherence: Field Testing and Psychometric Validation  awarded by CHILDREN'S HOSPITAL (BOSTON) 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Airways Clinical Research Center (ACRC)  awarded by American Lung Association 2016 - 2017
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^ 2016 - 2017
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^ 2015 - 2016

    • Education And Training

  • Doctor of Medicine, Medical University of South Carolina 1995
  • University of Florida, Internship 1996
  • University of Florida, Residency 1998
  • University of Florida, Postdoctoral Fellowship 2001

    • Full Name

  • Isabel Virella-Lowell